HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Clinical trials for HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER trials appear
Sign up with your email to follow new studies for HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Antibody-Drug combo takes aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload…
Matched conditions: HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo enters human testing
Disease control Recruiting nowThis early-phase study tests whether combining two drugs, Cirtuvivint and Olaparib, is safe for women with ovarian cancer that no longer responds to platinum chemotherapy. About 50 participants will take the medications on different schedules and visit the clinic regularly for ch…
Matched conditions: HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo aims to extend remission in ovarian cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, b…
Matched conditions: HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo trial offers hope for ovarian cancer patients
Disease control Recruiting nowThis study tests an experimental drug called IMGN151, alone or with other cancer treatments, in about 377 adults with gynecologic cancers like ovarian cancer. The goal is to check safety and find the best dose. Participants get the drug through an IV and will have regular check-u…
Matched conditions: HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for recurrent ovarian cancer? early trial combines novel PARP inhibitor with chemo
Disease control Recruiting nowThis early-stage study tests a new experimental drug (NMS-03305293) combined with a standard chemotherapy (topotecan) in about 24 people whose ovarian cancer has returned after previous treatments. The main goals are to check safety and find the best dose, while also seeing if th…
Matched conditions: HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Phase: PHASE1 • Sponsor: Nerviano Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Radioactive 'Bullets' aim to stop ovarian cancer spread in new trial
Disease control Recruiting nowThis study tests a single injection of Radspherin®, a radioactive treatment given directly into the abdomen, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has spread to the lining of the belly. About 114 participants will receive either stand…
Matched conditions: HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Phase: PHASE2 • Sponsor: Oncoinvent Solutions AS • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug targets Hard-to-Treat cancers in large trial
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…
Matched conditions: HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for ovarian cancer: drug combo targets resistant tumors
Disease control Recruiting nowThis study tests a new drug called IN10018 combined with standard chemotherapy in people with a tough-to-treat type of ovarian cancer that no longer responds to platinum-based drugs. About 150 adults will take part to see if the combination is safe and shrinks tumors. The goal is…
Matched conditions: HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for ovarian cancer: experimental drug AZD5335 faces off against standard care
Disease control Recruiting nowThis Phase 3 trial is testing a new drug called AZD5335 against standard treatments (like chemotherapy or another targeted drug) in about 1,100 women with a tough-to-treat type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if AZD…
Matched conditions: HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo shows promise for Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis phase 2 trial is testing a combination of the targeted drug mirvetuximab soravtansine and the chemotherapy carboplatin as a first treatment for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific marker (folate receptor alpha). About…
Matched conditions: HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 26, 2026 15:12 UTC
-
Can a simple test predict ovarian cancer treatment success?
Knowledge-focused Recruiting nowThis study is testing two genetic tests (Giscar and myChoice) to see if they can identify ovarian cancer patients whose tumors have a specific DNA repair problem (HRD). The goal is to see if these tests can predict which patients will respond well to platinum chemotherapy and may…
Matched conditions: HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:47 UTC